Spinal Fluid Inflammatory Proteins Reveal Why ALS Progresses at Different Speeds

Amyotrophic lateral sclerosis is one of the most merciless diagnoses in medicine, and one of its cruelest features is unpredictability. Two patients who appear nearly identical at the clinic, with similar ages, similar sites of symptom onset, and similar functional scores, can follow radically different trajectories: one may lose the ability to walk and breathe within a year, while another survives many years with comparatively slow deterioration. A new study published in the Journal of Neurology by a team at Xuanwu Hospital of Capital Medical University in Beijing offers a fresh clue to this puzzle, reporting that the inflammatory protein landscape of cerebrospinal fluid differs measurably between patients whose disease races ahead and those whose disease creeps. The findings suggest that neuroinflammation is not a vague background hum in ALS but a structured, quantifiable signature that tracks with the tempo of motor neuron loss.

The research, led by co-first authors Congwen Lv and Wenjia Zhu under the senior guidance of Wenjia Zhu and Yuwei Da, focused on a deceptively simple question: if inflammation genuinely matters in ALS, can its chemical fingerprints in the fluid bathing the brain and spinal cord distinguish fast progressors from slow ones? To answer it, the team enrolled 77 patients with ALS and stratified them by disease progression rate, a standard prognostic measure calculated from how quickly patients lose points on the revised ALS Functional Rating Scale. Forty patients fell into the slow-progressor group and thirty-seven into the fast-progressor group. This stratification matters because progression rate has repeatedly been shown to predict survival more reliably than almost any other clinical variable at diagnosis, making it the natural target for biomarker discovery.

Technically, the study leaned on a modern proteomic platform known as the Olink Target 96 Inflammation panel, which uses proximity extension assays to quantify dozens of inflammatory proteins from tiny volumes of cerebrospinal fluid. In a proximity extension assay, antibodies directed against each target protein carry short DNA tags; when two antibodies bind the same protein molecule, their tags join and can be amplified and counted by sequencing, converting protein abundance into a digital signal. This approach allows simultaneous, multiplexed measurement of chemokines, cytokines, tumor necrosis factor superfamily members, and matrix metalloproteinases with high sensitivity and minimal sample consumption, a decisive advantage when working with cerebrospinal fluid, which can only be obtained by lumbar puncture and is available in limited quantities.

The first analytical pass used limma, a statistical framework originally developed for genomics that models differential expression with empirical Bayes moderation, stabilizing variance estimates when sample sizes are modest. Comparing slow and fast progressors, the researchers identified eleven differentially expressed inflammatory proteins. Functional enrichment analysis of these proteins pointed squarely at chemokine signaling, tumor necrosis factor-related responses, and the NF-κB pathway, a transcriptional hub long implicated in glial activation and motor neuron injury. That convergence is biologically telling: chemokines orchestrate the recruitment and positioning of immune cells within the central nervous system, tumor necrosis factor family signaling can drive both apoptotic and inflammatory cascades, and NF-κB sits at the crossroads of nearly every neuroinflammatory response studied in ALS models.

Identifying proteins that differ between groups is only the first step; the team then asked which of them best predict the progression phenotype when forced to compete with one another. For this they turned to elastic net analysis, a penalized regression technique that blends the properties of ridge and lasso penalties. Elastic net is well suited to proteomic data, where dozens of candidate markers are correlated with each other and the number of predictors approaches the number of patients, because the penalty shrinks unstable coefficients toward zero and selects a parsimonious set of features rather than an overfitted laundry list. From this procedure emerged twelve candidate proteins, and among them nine showed positive associations with the slow-progressor phenotype: CST5, CCL11, SIRT2, CD6, CCL4, MMP-1, TNFRSF9, CCL19, and MCP-4.

Several of these names carry weight in the ALS literature. CCL11, also known as eotaxin, and the chemokines CCL4 and CCL19 belong to the chemokine family whose cerebrospinal fluid alterations had previously been linked to clinical course in smaller studies. SIRT2, a NAD-dependent deacetylase, is a particularly intriguing entry: it has been described as a suppressor of microglial activation and brain inflammation in experimental systems, yet its role in neurodegeneration remains contested, with some studies suggesting neuroprotective properties and others pointing in the opposite direction. MMP-1, a matrix metalloproteinase capable of remodeling extracellular matrix and modulating inflammatory access to neural tissue, has a documented history of dysregulation in ALS serum and cerebrospinal fluid. TNFRSF9, better known as CD137, participates in T-cell costimulation, hinting that adaptive immune signaling may be woven into the progression signature rather than only innate inflammation.

The most clinically consequential result came when the researchers combined the strongest proteomic candidates with basic clinical variables. A model incorporating SIRT2, MMP-1, body mass index, and site of onset achieved an apparent area under the receiver operating characteristic curve of 0.769, with a 95 percent confidence interval of 0.662 to 0.876. Recognizing that apparent performance in the same dataset used for model building is almost always optimistic, the team applied bootstrapping to estimate an optimism-corrected area under the curve of 0.729. In plain terms, the model correctly ranked a randomly chosen slow progressor above a randomly chosen fast progressor roughly seventy-three percent of the time after correction for overfitting. That is far from a perfect discriminator, but it is a meaningful signal for a disease in which prognostication at diagnosis remains notoriously difficult, and it was achieved with only two proteins and two routinely collected clinical parameters.

The interpretive claim the authors emphasize is perhaps the study’s most important contribution: the inflammatory signature appears to reflect genuine biological heterogeneity in ALS rather than nonspecific neurodegeneration. Neurofilament light chain, the most established fluid biomarker in ALS, tracks the amount of axonal damage already done, whereas the inflammatory proteins identified here seem to index the biological milieu in which that damage unfolds. If confirmed, this distinction would mean that cerebrospinal fluid inflammation carries prognostic information that is complementary to, rather than redundant with, neurodegeneration markers. It also dovetails with a growing body of work showing that immune traits, from neutrophil-to-lymphocyte ratios in blood to inflammatory profiles in plasma, correlate with survival and progression in ALS cohorts, and with recent plasma proteomic studies that have identified candidate biomarker panels predictive of the disease.

Why would higher levels of certain inflammatory proteins associate with slower rather than faster progression? The answer may lie in the increasingly nuanced view of neuroinflammation in ALS, in which the same signaling pathways can be harmful or protective depending on timing, cell type, and context. NF-κB activation in astrocytes, for example, has been shown in experimental models to drive a stage-specific beneficial neuroimmunological response, and some inflammatory activity may represent a compensatory, tissue-protective reaction rather than a purely destructive one. The positive association between the nine proteins and the slow-progressor phenotype is consistent with the idea that an engaged, regulated immune response may accompany a more contained disease course, while the absence of such a response, or a qualitatively different one, may permit unchecked degeneration. The authors are careful, however, not to overclaim causality from a cross-sectional comparison.

The limitations are clearly acknowledged and worth restating. The cohort comprised seventy-seven patients from a single center, the design was cross-sectional, and the stratification into slow and fast progressors, while clinically grounded, is a simplification of a continuous variable. The optimism-corrected performance estimate, though methodologically sound, still derives from the same dataset rather than an external validation cohort, and the authors explicitly state that SIRT2 and MMP-1 warrant further investigation as components of progression-stratification models but require validation in larger, longitudinal, and independent cohorts. Data from the study are available upon reasonable request to qualified researchers, which should facilitate replication efforts. Funded by the National Natural Science Foundation of China and approved by the ethics committee of Xuanwu Hospital with written informed consent from all participants, the study exemplifies a careful, hypothesis-driven use of multiplex proteomics in a disease that desperately needs stratification tools.

The practical stakes are high. Clinical trials in ALS have repeatedly been complicated by heterogeneity, with slow progressors diluting apparent treatment effects and fast progressors overwhelming them, and regulatory agencies and trial designers have increasingly called for biomarker-based stratification to enrich cohorts and reduce sample sizes. A validated cerebrospinal fluid inflammatory panel could, in principle, help assign patients to trials matched to their expected trajectory, serve as stratification factors in randomization, and even function as pharmacodynamic readouts for anti-inflammatory or immunomodulatory therapies. Lumbar puncture is more invasive than a blood draw, which limits routine deployment, but for a disease as heterogeneous and lethal as ALS, a spinal fluid signature that captures the biology of progression, anchored by proteins such as SIRT2 and MMP-1 and refined by machine-learning selection methods, represents exactly the kind of translational bridge between bench and bedside that the field has been seeking. The next test will come from independent longitudinal cohorts, and if the signature holds, the unpredictable course of ALS may become a little less mysterious.

Subject of Research: Cerebrospinal fluid inflammatory proteomic biomarkers associated with disease progression rate in amyotrophic lateral sclerosis

Article Title: Cerebrospinal fluid inflammatory proteomic profiling identifies biomarkers linked to disease progression in amyotrophic lateral sclerosis

Article References: Lv, C., Zhu, W., Wen, X., Wang, Y., Xie, N., Liu, H., Jiang, Y., Zou, W., Liu, Q., Gou, J., Yu, X., Di, L., Lu, Y., Wang, M., Xu, M., Chen, H., Duo, J., Huang, Y., & Da, Y. (2026). Cerebrospinal fluid inflammatory proteomic profiling identifies biomarkers linked to disease progression in amyotrophic lateral sclerosis. Journal of Neurology, 273(10), Article 638. https://doi.org/10.1007/s00415-026-14178-1

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14178-1

Keywords: amyotrophic lateral sclerosis, cerebrospinal fluid, neuroinflammation, biomarkers, proteomics, Olink, SIRT2, MMP-1, chemokines, NF-kB, disease progression, elastic net